CDA | Evidence Driven
CDA | Evidence Driven

durvalumab, carboplatin, paclitaxel

Details

Generic Name:
durvalumab, carboplatin, paclitaxel
Project Status:
Pending
Therapeutic Area:
Endometrial cancer that is mismatch repair deficient (dMMR)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi
Project Line:
Reimbursement Review
Project Number:
PC0366-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by: Imfinzi as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) Imfinzi in combination with olaparib with endometrial cancer that is mismatch repair proficient (pMMR)
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 4, 2024